Detalhe da pesquisa
1.
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study.
Oncologist
; 25(8): e1158-e1169, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452601